Last Updated: May 13, 2026

Patent: 10,336,814


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,336,814
Title:Method for obtaining thin fibril collagen by contacting native collagen with an antibody
Abstract:A collagen material having a form of thin fibrils generally free of fibril-bundling proteogylcan interactions, and a method for providing the thin fibril collagen material from native collagen fibers. The method uses proteoglycan antibodies to disassociate the proteoglycan interactions in bundled collagen fibrils to provide the constituent fibrils. The process can be used as a model for arthritis and the resulting fibrils can be used to form new extracellular matrix biomaterials and new tissues.
Inventor(s):Joseph Orgel, Olga Antipova
Assignee: Matrix Odyssey LLC
Application Number:US15/257,089
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 10,336,814: Claims and US Patent Landscape Analysis

What does US 10,336,814 claim?

US Patent 10,336,814 is a granted US utility patent with claim scope defined by its independent claims, constrained by its specification and prosecution history. Without the patent’s claim set (independent and dependent claims), the precise technical subject matter, elements, and claim construction cannot be reproduced or validated. The same limitation applies to identifying which elements are novel versus known in the art, and to mapping each claim to specific prior-art patents or non-patent literature.

What is the patent’s practical claim boundary?

Claim boundaries in US practice depend on:

  • Claim language (element-by-element)
  • Specification support (for narrowing during construction)
  • Prosecution record (for estoppel and disclaimer)
  • Litigation posture (if any)

A landscape analysis that is actionable for R&D or investment requires those specifics, including claim charting against prior art and the identification of enforceable claim scope after any amendments. Those documents are not available in the input provided.

How does the US patent landscape look around 10,336,814?

A credible landscape needs at minimum:

  • Forward citations (other patent families that cite 10,336,814)
  • Backward citations (prior families cited by 10,336,814)
  • Same-family continuations (continuation-in-part, continuation, divisional, related filings)
  • Competing claim space (granted and pending US applications likely to overlap)
  • Claim similarity clustering (technology-class and text-based similarity)
  • Freedom-to-operate risk map (where independent claims read onto likely products/processes)

None of these can be completed accurately without the patent’s title/abstract, claim text, CPC/US classifications, cited references list, and the family members.

Are there close prior-art patents that narrow or invalidate parts of the claims?

This requires claim-by-claim identification of:

  • What the independent claims require (system/method composition, steps, components)
  • Which limitations are likely to be found in earlier patents
  • Whether earlier disclosures anticipate under 35 USC 102 or render obvious under 35 USC 103
  • Whether the patent’s novelty is in a particular parameter range, architecture, sequence of steps, or material choice

Those determinations cannot be made without the claims and cited references.

Which adjacent patents increase infringement risk or enable design-arounds?

Risk evaluation depends on:

  • Whether nearby patents include claim elements that overlap with the independent claim core
  • Whether nearby patents carve out the same design choices with different parameter values, architectures, or sequences
  • Whether independent claims in nearby patents are broad enough to cover the same commercial embodiments

No overlap mapping can be produced without the claim set and the adjacent patent corpus.

What is the best actionable use of 10,336,814 in R&D?

To extract actionable value, an analysis must produce:

  • A claim-element checklist for assay designs and prototype targeting
  • A design-around matrix (which claim limitations to avoid)
  • A claim strength profile (where claims appear weakest due to prior art, indefiniteness risk, or known prosecution narrowing)
  • A product scoping guide (what embodiments likely fall inside claim scope)

Those deliverables require the actual claim language and prosecution-linked narrowing.


Key Takeaways

  • A comprehensive, critical analysis of US Patent 10,336,814 requires the patent’s claim text and citation/prosecution record to map scope, novelty, and risk.
  • A landscape that supports high-stakes R&D or investment decisions also requires forward/backward citation data and family/pending competitor mapping, which cannot be generated from the patent number alone in this context.

FAQs

1) Can you summarize the independent claims of US 10,336,814?

Not from the information provided. Independent claims must be quoted or reliably reconstructed from the claim text.

2) Does US 10,336,814 cover a method, product, or system?

Not determinable without the patent’s description and claims.

3) What prior patents are closest to US 10,336,814?

Not determinable without the patent’s cited references and classification/cpc data.

4) What is the likelihood that key limitations are anticipated under 35 USC 102?

Not determinable without claim language and identified prior-art disclosures.

5) How should a company use this patent for design-around planning?

A design-around plan requires an element-by-element claim chart against relevant prior art and competitor claims, which cannot be prepared without the patent’s claims and citations.


References

[1] None (no patent text, citations, classifications, or prosecution documents were provided in the input).

More… ↓

⤷  Start Trial

Details for Patent 10,336,814

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Takeda Pharmaceuticals U.s.a., Inc. VPRIV velaglucerase alfa For Injection 022575 February 26, 2010 ⤷  Start Trial 2036-09-06
Genentech, Inc. ACTEMRA tocilizumab Injection 125276 January 08, 2010 ⤷  Start Trial 2036-09-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.